Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
- J. Immunother. Cancer, Mar 13 2024, 12 (3) e008638 | https://doi.org/10.1136/jitc-2023-008638